Orum Therapeutics, Inc. (KOSDAQ:475830)

South Korea flag South Korea · Delayed Price · Currency is KRW
86,300
+8,700 (11.21%)
Apr 10, 2026, 3:30 PM KST
Market Cap1.83T +190.9%
Revenue (ttm)23.56M -99.9%
Net Income-41.97B
EPS-2,017.00
Shares Out21.23M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume357,800
Average Volume291,821
Open79,500
Previous Close77,600
Day's Range79,000 - 88,100
52-Week Range15,950 - 146,600
Betan/a
RSI40.88
Earnings DateApr 3, 2026

About Orum Therapeutics

Orum Therapeutics, Inc., a biopharmaceutical company, engages in the research and development of pharmaceuticals for cancer and immune diseases. The company develops BMS-986497 (ORM-6151), which is in phase 1 clinical trial to treat acuta myeloid leukemia and high-risk myelodysplastic syndromes; ORM-1153, which is in preclinical trial to treat acuta myeloid leukemia and heme-onc; and ORM-1023, which is in preclinical trial for the treatment of small cell lung cancer and neuroendocrine tumor. It also develops multiple programs; and E3 Ligase-DAC... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2016
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 475830
Full Company Profile

Financial Performance

In 2025, Orum Therapeutics's revenue was 23.56 million, a decrease of -99.89% compared to the previous year's 20.91 billion. Losses were -41.97 billion, 631.2% more than in 2024.

Financial Statements